

OCT 101

GREGORY D. SEARCY, M.D. ERDEY SEARCY EYE GROUP COLUMBUS, OHIO



How OCT Works

- Light beam is simultaneously sent into the eye and a referen mirror
- The light penetrates through the ocular tissue layers and is back (altered)
- The returning light is compared (interferometry) to the reference light (un-altered), generating an image of the underlying tissue
- ► This provides cross-sectional imaging of tissue morphology in viv



Ocular Coherence Tomography

- Carl Zeiss Cirrus 400
- Imaging: HD-OCT
- Methodology: Spectral Domain OCT
- Scan speed: 27,000 A-Scans per second
- A-Scan depth: 2 mm
- Axial resolution: 5 um
- Iransverse resolution: 15 um
- Non-contact, high resolution tomographic and biomicroscopic imaging device








Image Display


- Resolution of 5-10 micrometers in tissue
 Display is in gray scale or false color scale
- Red-white high reflectivity (RPE and RNFL)
 Blue-green low reflectivity (Ganglion cells, Photoreceptors (
 Choroid)


Normal Macula and OCT










































































































Inflammatory CME

- Intraretinal edema contained in honey-comb like spaces between cells
- Abnormal perifoveal retinal capillary permability
 FA: Multiple small focal fluorescein leaks with late pooling of dye in extracellular spaces
- OCT: diffuse retinal thickening with cystic areas of low reflectivity in inner nuclear and outer plexiform layers
 Severe cases may have subretinal fluid or optic nerve head swelling

CME


- 82 year old female 6months s/p cataract surger
- Vision started out great


CME





CME

- Had been using Predforte and Bromfenac for two weeks wit minimal reponse in edema.
- ► Subtenons kenalog 40mg in the office










VMT

63 year old caucasion female

4/22/16 VA OS 20/200




Accular hole \$/26/16 Returned for Jefrea VA 20/100



Addression <

Plaquenil Toxicity


- Hydroxychloroquine sulfate Plaquenil (99%) and chloroquin are commonly used for rheumatologic disorders (SLE, RA, et WHO Model List of Essential Medicines e (1%)
- An irreversible and potentially blinding toxic retinopathy is a "rare" adverse event that may occur with long-term use in 0.1-1%.
- This was based on short term studies and on end-stage observ such as visible retinal damage (bull's eye maculopathy)





Elongated fibroblast-like cells or palisading histiocytes around a necrotic center oriented with their long axes perpendicular to the center of the nodule, surrounded by a lymphocytic infiltrate

Rheumatoid Arthritis Keratoconjunctivitis Sicca



Plaquenil – Mechanism of Action

- HCQ is a weak base that easily crosses plasma membranes
- HCQ accumulates (1000 X) in lysosomes (acidic cytoplasmic vesicles)
- This pH change in turn inhibits lysosomal acidic proteases or proteolysis
- Decreased intracellular processing, glycosylation and secretion or proteins important for inflammation and immunity
 Decreased immune functions such as chemotaxis, phagocytosis and superoxide production by PMN
- Inhibits APC association of class II MHC molecules with autoantigens and therefore antigen presentation

Ocular Immunology – Cellular Components

- - Process to a peptide epitope
 Present in Ag binding groove of MHC



Plaquenil Toxicity

Plaquenil Toxicity

- Progressive toxic effects for up to 7 years after discontinuation
 Little or no recovery of vision loss!

- We now have more sensitive methods to detect early toxicity with SD-OCT, mfERG, 10-2 visual fields and FAF

Plaquenil Toxicity

- Cumulative dose > 1000g (total) 1000g/0.4g = 2,500 days or 7
- > 400 mg/day (200 mg PO BID)
 > 6.5 mg/kg ideal body weight

Plaquenil Toxicity


- - > 400mg/day
 Real body weight > 5 mg/kg


 - Ideal body weight > 55 mg/kg
 Women 100 lb for first 5 feet, plus 5 lb for every inch of height over 5 feet
 Men 110 lb for first 5 feet, plus 5 lb for every inch of height over 5 feet


Plaquenil Toxicity


- Ideal body weight -> 6.5 mg/kg
 Women 100 lb for first 5 feet, plus 5 lb for every inch of height over 5 feet
 Men 110 lb for first 5 feet, plus 5 lb for every inch of height over 5 feet

Plaquenil toxicity
































Macular degeneration

- Age-related macular degeneration: Drusen, RPE changes, rule-out net
- Visual loss in dry ARMD is due to localized thinning of the photoreceptor layer immediately above the drusen
 SD-OCT instruments can accurately distinguish the presence an size of drusen and RPE changes, making it possible to differentia the different retinal layers.

В

Macular degeneration



- (A) Photography: Central hard dusan surrounded by areas of RPE atrophy
 (B) Autofluorescence image: hypofluorescence area corresponding to atrophic areas of the RPE
 - (C)OCT: Two hyperreflective points corresponding to hard drusen
 - (D) OCT infrared imag

Macular degeneration

- Because of the widespread use of OCT, the use of fluorescein angiography has dropped to second place in routine consultations
 FA is still an essential exam for studying CNV in patients with AMD, and FA and ICGA are especially important in identifying occult disease.
 - and ICGA are especially important in identifying occult disease.
 AMD
 - Normal

<text><text>

Macular degeneration

- OCT is fundamental in the management of macular degeneration
- Since the introduction of PDT as an antiangiogenic agent a decade ago, OCT has provided information on the activity of neovascular membranes and determines the need to establish freatablish treatment response, and early signs of recurrence or resolution.
- Several multicenter studies were designed to evaluate treatment protocols of antiangiogenic therapies that rely on OCT as the main criteria for retreatment.

Macular degeneration

- The injection protocols established in multicenter phase III studie Lucentis for neovascular AMD, the ANCHOR and MARINA trials consisted of monthly intravitreal injections for 2 years for all studthat resulted in substantial gains in VA in various intermediate ac and at the final examination. However, the dose of 24 injections a human and economic burden that made it difficult and import to administer.
- In phase I and II studies of Lucentis before these studies, an extension study was conducted in which administration of new additional doses were left to the discretion of the investigator based on the presence of diffusion on FA or intrarefinal or subrefinal fluid on OCT. This subanalysis showed that often the presence of retinal fluid could be adected much earlier by OCT than FA, leaving the door open for a greater role of OCT in treatment.

Macular degeneration "Treat and Observe" dosing


- Three monthly loading doses, monthly anti-VEGF injections are administered for 2 years according to the following criteria:

 Decrease of 5 letters of vision and fluid on OCT
 Increase of 100 microns in central retinal thickness on OCI 3. Macular hemorrhage
 Classic CNV in emerging FA
 Persistent fluid on OCT in month after the last injection


 VA results were similar to monthly anti-VEGF for 2 years, but required significantly fewer injections [5.6 vs 12 in 1st year, 9.9 vs 24 total).
- The good results with fewer injections based on OCT led to inclusion of OCT as a primary criteria in new multicenter studies such as the SAILOR or SUSTAIN studies.

Macular degeneration "Treat and Extend" dosing


- Three monthly leading doses, which are continued monthly until Stable visual acuity Absence of macular hemorrhage Dry OCT
- Patients then continue to receive regular maintenance inject increasing intervals, extended to 6 weeks. Visual acuity, clinic findings, and OCT changes are recorded again and patients receive an injection regardless of the presence or absence o disease activity.
- If stable, interval to the next visit (and injection) is extended to 7-8 weeks.
- If evidence of renewed disease activity, interval is shortened.





Wet macular degeneration



OCT visualizes the neovascu retinal pigme Picture D. Drusencid RPE detachments (Δ) subretinal hemorrhage (,) dense particles in subretinal fluid (1) intraretinal migration of RPE cells (>)







#